Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apollomics Inc. - Class A Ordinary Shares
(NQ:
APLM
)
6.000
-0.710 (-10.58%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Apr 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apollomics Inc. - Class A Ordinary Shares
< Previous
1
2
3
4
5
Next >
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 25, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 10, 2024
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR...
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
April 01, 2024
Via
Benzinga
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 28, 2024
From
Apollomics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 26, 2024
Via
Benzinga
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 26, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 07, 2024
Via
Benzinga
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Apollomics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 06, 2024
Via
Benzinga
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
January 19, 2024
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
January 17, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 12, 2024
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 09, 2024
Via
Benzinga
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the 2024 Biotech Showcase
January 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 04, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
November 30, 2023
Shares of Salesforce, Inc.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
November 30, 2023
It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!
Via
InvestorPlace
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
November 29, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 27, 2023
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
November 27, 2023
Shares of UP Fintech Holding Limited (NASDAQ: TIGR) surged in pre-market trading after the company results for the third quarter.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 27, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 27, 2023
It's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 22, 2023
Via
Benzinga
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
November 17, 2023
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.